Aug 2026
Caged Glycan-Antibody Conjugates for Tumor-Selective Activation of Lysosome-Targeting Chimeras.
A chemically activatable LYTAC platform that leverages tumor microenvironment-specific cues to achieve precise and safe protein degradation in vivo is reported, significantly enhancing the safety and therapeutic window of lysosome-targeted degradation strategies in cancer therapy.
Mohan Chen, Yi-Cun Li, Xue-Ting Wei et al.
· Journal of Medicinal Chemist... · 0 citations